PUBLIC COMPANY
save$TPSTTempest Therapeutics, Inc.
$TPSTBrisbane, CA, USupdated 2mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Preclinical1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
- phase3A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
- phase1TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
🐶 Hiring Signal
News
- An eye drug biotech banks $118M and stocks its executive suiteClaris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.biopharma_dive · 2mo ago
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that